20° Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

27.94 -0.92 (-3.19%)

Streaming Delayed Price Updated: 10:22 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

July 11, 2025

From Gibbs Mura

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

July 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

July 11, 2025

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Capricor Therapeutics Hammered On A Surprise FDA Rejection ↗

July 11, 2025

The company is currently running another study with results due in the third quarter.

Via Investor's Business Daily

There are notable gap-ups and gap-downs in today's session. ↗

July 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock ↗

July 11, 2025

FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.

Via Benzinga

Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy ↗

July 11, 2025

The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and...

Via Stocktwits

Wondering what's happening in today's pre-market session? ↗

July 11, 2025

The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket ↗

July 11, 2025

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’ ↗

July 08, 2025

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

July 03, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

June 30, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

June 28, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

June 25, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

June 24, 2025

Via ACCESS Newswire

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy ↗

June 24, 2025

Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, 2025.

Via Benzinga

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning ↗

June 24, 2025

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Via Stocktwits

Why Is Capricor Therapeutics Stock Trading Lower On Monday? ↗

June 23, 2025

Capricor stock drops as FDA cancels advisory meeting on Duchenne therapy; leadership changes and regulatory tensions fuel uncertainty.

Via Benzinga

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients ↗

June 20, 2025

Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-06-20: top gainers and losers in today's session. ↗

June 20, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 20, 2025

Via Benzinga

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data ↗

June 20, 2025

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Via Stocktwits

Gapping stocks in Friday's session ↗

June 20, 2025

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

June 20, 2025

Via ACCESS Newswire

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 20, 2025

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

All News about Capricor Therapeutics, Inc. - Common Stock

Sections

Services